|
Diabetic Nephropathy
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Connective tissue growth factor (CTGF) levels are up-regulated in patients with DN and in renal tubular epithelial cells (RTECs) exposed to high glucose (HG).
|
31773302 |
2020 |
|
Diabetic Nephropathy
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Our previous study demonstrated that fibroblast growth factor 21 (FGF21) prevented DN associated with the suppressing renal connective tissue growth factor expression, a key marker of renal fibrosis.
|
31701691 |
2020 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
We have detected the expression of YAP, TEAD and CTGF in normal people (n=10) and patients with DN (n=51) by immunohistochemical and immunofluorescence staining and evaluated the relationship among clinical, pathologic data and YAP expression in type 2 diabetic nephropathy.
|
30720184 |
2019 |
|
Diabetic Nephropathy
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
These above data suggested that overexpression of SHIP might be a potent method to lessen renal extracellular matrix accumulation via inactivation of PI3K/Akt pathway and suppression of CTGF expression in DKD.
|
27965087 |
2017 |
|
Diabetic Nephropathy
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, blocking CTGF by specific antibody reduced albuminuria, prevented the overexpression of CTGF, as well as β-catenin, in glomeruli and subsequently ameliorated podocyte EMT in DN mice.
|
28370212 |
2017 |
|
Diabetic Nephropathy
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We found prominent lymphangiogenesis during tubulointerstitial fibrosis to be associated with increased expression of CTGF and VEGF-C in human obstructed nephropathy as well as in diabetic kidney disease.
|
28545716 |
2017 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
By determining the expression of transforming growth factor-β1 (TGF-β1), connective tissue growth factor (CTGF), collagen type IV (ColIV) and fibronectin (FN) levels in high glucose-cultured glomerular mesangial cells (MCs), the present study aimed to assess the anti-proliferative and anti-fibrotic effects of SIT on the therapeutic potential for the prevention of DN and its mechanism.
|
29042993 |
2017 |
|
Diabetic Nephropathy
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
This study was to determine whether miR-30c was involved in the mechanism of renal fibrosis by inhibiting target CTGF expression in DN.
|
26775556 |
2016 |
|
Diabetic Nephropathy
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In this review, we only focus on the potential renoprotective therapeutic agents which can specifically abolish CCN2 expression or nonspecifically inhibit CCN2 expression for retarding the development and progression of DN.
|
26421309 |
2015 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
We aimed to identify microRNAs (miRNAs) targeting CTGF on podocytes in diabetic nephropathy.
|
26063197 |
2015 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Elevated Urinary Connective Tissue Growth Factor in Diabetic Nephropathy Is Caused by Local Production and Tubular Dysfunction.
|
26171399 |
2015 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Urine CTGF may be a good marker for the prediction of diabetic nephropathy.
|
24192280 |
2013 |
|
Diabetic Nephropathy
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
TGFβ and CCN2 attenuate CREB and augment E2F1 transcriptional activation with the likely effect of altering actin cytoskeletal and cell growth/hypertrophic gene activity with implications for cell dysfunction in diabetic kidney disease.
|
23902294 |
2013 |
|
Diabetic Nephropathy
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Hyperglycemia causes renal cell damage via CCN2-induced activation of the TrkA receptor: implications for diabetic nephropathy.
|
22586581 |
2012 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
CTGF/CCN2 activates canonical Wnt signalling in mesangial cells through LRP6: implications for the pathogenesis of diabetic nephropathy.
|
21237163 |
2011 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
RGD |
XLF-III-43, a novel coumarin-aspirin compound, prevents diabetic nephropathy in rats via inhibiting advanced glycation end products.
|
19895808 |
2010 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Excessive growth of glomerular mesangial cells and overexpression of transforming growth factor-beta1 (TGF-beta1) and connective tissue growth factor (CTGF) are the pathological features of diabetic nephropathy.
|
20460752 |
2010 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
RGD |
Irbesartan ameliorates diabetic nephropathy by reducing the expression of connective tissue growth factor and alpha-smooth-muscle actin in the tubulointerstitium of diabetic rats.
|
19065061 |
2009 |
|
Diabetic Nephropathy
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
BMP signaling and podocyte markers are decreased in human diabetic nephropathy in association with CTGF overexpression.
|
19255250 |
2009 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
LHGDN |
Plasma CTGF contributes significantly to prediction of ESRD and mortality in patients with type 1 diabetic nephropathy.
|
18344285 |
2008 |
|
Diabetic Nephropathy
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice.
|
18075496 |
2008 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Unraveling the role of connective tissue growth factor in diabetic nephropathy.
|
18235518 |
2008 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Long-term inhibition and targeting TGFbeta(1) directly is problematic, therefore, a more fruitful direction targeting diabetic nephropathy may involve the development of therapeutic strategies specifically targeting CTGF.
|
17300978 |
2008 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Treatment with the CTGF ASO for 8 wk reduced serum creatinine and attenuated urinary albuminuria and proteinuria in diabetic db/db mice, a model of type 2 DN.
|
17554073 |
2007 |
|
Diabetic Nephropathy
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Connective tissue growth factor (CTGF/CCN2) is thought to play a role in normal wound repair and bone remodeling, but also promotes fibrosis in several disease processes including diabetic nephropathy, sclerodoma and pancreatitis.
|
17786299 |
2007 |